S1PR1 and multiple sclerosis: In particular, the discovery of novel agents that target S1P1 drove an intense focus on the role of S1P1 in lymphocyte trafficking and led to several FDA approved S1P1 modulating agents4, most notably Fingolimod (FTY720)5, for the management of multiple sclerosis.